Opinion|Videos|February 19, 2024
Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life
Author(s)Rana R. McKay, MD, Neal Shore, MD, FACS
Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
lan M. Thompson Jr, MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL
2
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
Dr Van Gorp on PFS Data With TUB-040 in Platinum-Resistant Ovarian Cancer
5